Can-Fite BioPharma Ltd (CANF)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Can-Fite BioPharma Ltd (CANF) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011917
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Can-Fite BioPharma Ltd (Can-Fite) is a biopharmaceutical company that offers pharmaceutical discovery and clinical development services. The company’s pipeline product portfolio includes CF101, CF102 and CF602. It develops its products by utilizing its platform technology based on the Gi protein coupled A3 adenosine receptor (A3AR) in inflammatory and cancer cells. Can-Fite developes drugs that are used in the treatment of various diseases such as cancer, sexual dysfunction, inflammatory diseases and ophthalmic indications. The company’s CF 102, is an oral drug used to treat liver cancer and CF 602, is an allosteric modulator used in the treatment of inflammatory diseases. It conducts Phase I, II and III clinical trials for various indications across the US and Israel. Can-Fite is headquartered in Petah-Tikva, Israel.

Can-Fite BioPharma Ltd (CANF) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 12
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 13
Merger 14
OphthaliX Merges with Wize Pharma 14
Licensing Agreements 15
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 15
Equity Offering 16
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 16
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 17
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 18
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 19
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 20
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 21
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 23
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 24
OphthaliX Withdraws Public Offering of Shares for USD10 Million 25
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 26
Denali Concrete Completes Private Placement Of Shares For Above US$6 Million 27
Acquisition 28
Denali Concrete Acquires EyeFite From Can-Fite BioPharma 28
Can-Fite BioPharma Ltd – Key Competitors 29
Can-Fite BioPharma Ltd – Key Employees 30
Can-Fite BioPharma Ltd – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 27, 2017: Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update 32
Sep 01, 2017: Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update 35
May 30, 2017: Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update 37
Mar 31, 2017: Can-Fite Reports 2016 Financial Results & Provides Clinical Update 39
Nov 25, 2016: Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update 41
Aug 26, 2016: Can-Fite Reports Financial Results for Six Months Ended June 30, 2016 43
May 27, 2016: Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update 45
Apr 01, 2016: Can-Fite Reports 2015 Financial Results & Provides Clinical Pipeline Update 47
Research And Development 49
Jun 05, 2017: Can-Fite BioPharma establishes clinical advisory board for NAFLD and NASH treatment 49
Product News 50
08/08/2016: Can-Fites Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology 50
01/11/2016: Can-Fite Announces Update on CF101 51
01/11/2016: Can-Fite Announces Update on CF102 52
Clinical Trials 53
Oct 13, 2016: Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH 53
Sep 13, 2016: Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial 54
Jul 25, 2016: Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD 55
Jul 05, 2016: OphthaliX Announces Phase II Glaucoma Data 56
Jun 15, 2016: Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects 57
Jun 07, 2016: Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101) 58
Jun 01, 2016: Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis 59
Mar 17, 2016: Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis 60
Jan 05, 2016: Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Can-Fite BioPharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Can-Fite BioPharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Can-Fite BioPharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Can-Fite BioPharma Enters into Distribution Agreement with Chong Kun Dang Pharma 12
Can-Fite BioPharma To Enter Into Co-Development Agreement With Smart Assays BioTech 13
OphthaliX Merges with Wize Pharma 14
Cipher Pharma Enters into Licensing Agreement with Can-Fite BioPharma for CF101 15
Can-Fite BioPharma Plans to Raise USD50 Million in Public Offering of Securities 16
Can-Fite Biopharma Files Registration Statement for Public Offering of Shares for up to USD5 Million 17
Can-Fite BioPharma Raises USD5 Million in Private Placement of ADSs 18
Can-Fite BioPharma Raises USD4.8 Million in Private Placement of Shares 19
Can-Fite BioPharma Raises USD9 Million in Private Placement of American Depository Shares 20
Can-Fite BioPharma Raises USD8 Million in Private Placement of American Depositary Shares 21
Can-Fite BioPharma Completes Private Placement Of American Depositary Shares For US$5 Million 23
Can-Fite BioPharma Completes Public Offering Of Units For US$6 Million 24
OphthaliX Withdraws Public Offering of Shares for USD10 Million 25
Can-Fite BioPharma Completes Public Offering Of Units For US$7.2 Million 26
Denali Concrete Completes Private Placement Of Shares For Above US$6 Million 27
Denali Concrete Acquires EyeFite From Can-Fite BioPharma 28
Can-Fite BioPharma Ltd, Key Competitors 29
Can-Fite BioPharma Ltd, Key Employees 30
Can-Fite BioPharma Ltd, Other Locations 31
Can-Fite BioPharma Ltd, Subsidiaries 31

★海外企業調査レポート[Can-Fite BioPharma Ltd (CANF)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Hartz Mountain Corporation:企業の戦略・SWOT・財務分析
    The Hartz Mountain Corporation - Strategy, SWOT and Corporate Finance Report Summary The Hartz Mountain Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Cavion LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Cavion LLC (Cavion), formerly Tau Therapeutics LLC is a clinical stage pharmaceutical company that develops modulators and drugs. The company researches and develops T-type calcium channel (Cav3) inhibitors for the treatment of neurologic and oncologic diseases. It provides pipeline products …
  • University of Tennessee Research Foundation-製薬・医療分野:企業M&A・提携分析
    Summary University of Tennessee Research Foundation (UTRF), a subsidiary of University of Tennessee is a non profit organization that promotes research and education. The organization offers agriculture, chemistry and materials; energy, animal health, engineering, human health, research tools and so …
  • Relay Medical Corp (CHX):企業の財務・戦略的SWOT分析
    Summary Relay Medical Corp(Relay), formerly Chromedx Corp, is a medical technology company that develops medical devices for in vitro diagnostics and point-of-care testing. The company offers technologies based on granted and pending patents such as HemoPalm and AUF. Its HemoPalm provides a combinat …
  • Star Gas Partners L.P.:企業の戦略・SWOT・財務分析
    Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Norsk Hydro ASA:企業のM&A・事業提携・投資動向
    Norsk Hydro ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Norsk Hydro ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Akonni Biosystems Inc:企業の製品パイプライン分析2018
    Summary Akonni Biosystems Inc (Akonni Biosystems) is a molecular diagnostics company that develops, manufactures, and distributes integrated molecular diagnostic systems. The company provides product such as nucleic acid extraction kits, molecular diagnostic tests, thermal cyclers, microarray reader …
  • Owens Corning:企業の戦略・SWOT・財務情報
    Owens Corning - Strategy, SWOT and Corporate Finance Report Summary Owens Corning - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • VAALCO Energy Inc (EGY):企業の財務・戦略的SWOT分析
    VAALCO Energy Inc (EGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • United Microelectronics Corporation (2303):企業の財務・戦略的SWOT分析
    United Microelectronics Corporation (2303) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Electricity Generating Authority of Thailand:電力:M&Aディール及び事業提携情報
    Summary Electricity Generating Authority of Thailand (EGAT) is a state-owned power utility. It generates, procures, transmits, and distributes electricity. The authority produces energy using hydro, coal, natural gas, diesel, fuel oil and palm oil, and renewable sources. EGAT procures electricity fr …
  • A-Cap Energy Ltd (ACB):企業の財務・戦略的SWOT分析
    Summary A-Cap Energy Ltd (A-Cap) is a mineral resources development company that acquires, explores, and develops mineral resource properties across Australia. It explores for coal and uranium deposits. Its projects include Letlhakane uranium project, the Mea coal project, and Foley coal project. A- …
  • Nippon Express Co Ltd (9062):企業の財務・戦略的SWOT分析
    Nippon Express Co Ltd (9062) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Gujarat State Electricity Corporation Ltd:企業の戦略的SWOT分析
    Gujarat State Electricity Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • RPP Infra Projects Ltd (RPPINFRA):企業の財務・戦略的SWOT分析
    RPP Infra Projects Ltd (RPPINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Luxair S.A.:企業の戦略・SWOT・財務情報
    Luxair S.A. - Strategy, SWOT and Corporate Finance Report Summary Luxair S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Idaho Power Co:発電所・企業SWOT分析
    Idaho Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Synmosa Biopharma Corp (4114):製薬・医療:M&Aディール及び事業提携情報
    Summary Synmosa Biopharma Corp (Synmosa) is a pharmaceutical company that manufactures, markets and distributes generic medicines. The company produces non-pharmaceutical products such as cosmeceutical and nutrition products, and food supplements in effervescent tablet and granule forms. It offers p …
  • Koch Enterprises, Inc.:企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Recipharm AB:企業のM&A・事業提携・投資動向
    Recipharm AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Recipharm AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆